Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin e Cancer Prevention Trial (SELECT)

Demetrius Albanes, Cathee Till, Eric A. Klein, Phyllis J. Goodman, Alison M. Mondul, Stephanie J. Weinstein, Philip R. Taylor, Howard L. Parnes, J. Michael Gaziano, Xiaoling Song, Neil E. Fleshner, Powel H. Brown, Frank L. Meyskens, Ian M. Thompson

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed higher prostate cancer incidence in men supplemented with high-dose α-tocopherol. We, therefore, examined whether presupplementation plasma α-tocopherol or γ-tocopherol was associated with overall or high-grade prostate cancer. A stratified case-cohort sample that included 1,746 incident prostate cancer cases diagnosed through June 2009 and a subcohort of 3,211 men was derived from the SELECT trial of 35,533 men. Plasma was collected at entry from 2001 to 2004, and median follow-up was 5.5 years (range, 0-7.9 years). Incidence of prostate cancer as a function of plasma α-tocopherol, γ-tocopherol, and supplementation with α-tocopherol or selenomethionine was estimated by the hazard ratio (HR). Plasma γ-tocopherol was not associated with prostate cancer. Men with higher α-tocopherol concentrations seemed to have risk similar to that of men with lower concentrations [overall HR for fifth (Q5) vs. first quintile (Q1), 1.21; 95 % confidence interval (CI), 0.88-1.66; P-trend = 0.24; in the trial placebo arm, Q5 HR, 0.85; 95% CI, 0.44-1.62; P-trend = 0.66]. We found a strong positive plasma α-tocopherol association among men receiving the trial selenomethionine supplement [Q5 HR, 2.04; 95% CI, 1.29-3.22; P-trend = 0.005]. A positive plasma α-tocopherol-prostate cancer association also seemed limited to high-grade disease (Gleason grade, 7-10; overall Q5 HR, 1.59; 95% CI, 1.13-2.24; P-trend = 0.001; among men receiving selenomethionine, Q5 HR, 2.12; 95% CI, 1.32-3.40; P-trend = 0.0002). Our findings indicate that higher plasma α-tocopherol concentrations may interact with selenomethionine supplements to increase high-grade prostate cancer risk, suggesting a biologic interaction between α-tocopherol and selenium itself or selenomethionine.

Original languageEnglish (US)
Pages (from-to)886-895
Number of pages10
JournalCancer Prevention Research
Volume7
Issue number9
DOIs
StatePublished - Sep 1 2014

Fingerprint

Tocopherols
Selenium
Vitamins
Prostatic Neoplasms
Selenomethionine
Neoplasms
Confidence Intervals
Incidence
Vitamin E
Placebos

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Albanes, D., Till, C., Klein, E. A., Goodman, P. J., Mondul, A. M., Weinstein, S. J., ... Thompson, I. M. (2014). Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin e Cancer Prevention Trial (SELECT). Cancer Prevention Research, 7(9), 886-895. https://doi.org/10.1158/1940-6207.CAPR-14-0058

Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin e Cancer Prevention Trial (SELECT). / Albanes, Demetrius; Till, Cathee; Klein, Eric A.; Goodman, Phyllis J.; Mondul, Alison M.; Weinstein, Stephanie J.; Taylor, Philip R.; Parnes, Howard L.; Gaziano, J. Michael; Song, Xiaoling; Fleshner, Neil E.; Brown, Powel H.; Meyskens, Frank L.; Thompson, Ian M.

In: Cancer Prevention Research, Vol. 7, No. 9, 01.09.2014, p. 886-895.

Research output: Contribution to journalArticle

Albanes, D, Till, C, Klein, EA, Goodman, PJ, Mondul, AM, Weinstein, SJ, Taylor, PR, Parnes, HL, Gaziano, JM, Song, X, Fleshner, NE, Brown, PH, Meyskens, FL & Thompson, IM 2014, 'Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin e Cancer Prevention Trial (SELECT)', Cancer Prevention Research, vol. 7, no. 9, pp. 886-895. https://doi.org/10.1158/1940-6207.CAPR-14-0058
Albanes, Demetrius ; Till, Cathee ; Klein, Eric A. ; Goodman, Phyllis J. ; Mondul, Alison M. ; Weinstein, Stephanie J. ; Taylor, Philip R. ; Parnes, Howard L. ; Gaziano, J. Michael ; Song, Xiaoling ; Fleshner, Neil E. ; Brown, Powel H. ; Meyskens, Frank L. ; Thompson, Ian M. / Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin e Cancer Prevention Trial (SELECT). In: Cancer Prevention Research. 2014 ; Vol. 7, No. 9. pp. 886-895.
@article{31dab5c6823141d1b8cb2bbeacdcefbf,
title = "Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin e Cancer Prevention Trial (SELECT)",
abstract = "The Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed higher prostate cancer incidence in men supplemented with high-dose α-tocopherol. We, therefore, examined whether presupplementation plasma α-tocopherol or γ-tocopherol was associated with overall or high-grade prostate cancer. A stratified case-cohort sample that included 1,746 incident prostate cancer cases diagnosed through June 2009 and a subcohort of 3,211 men was derived from the SELECT trial of 35,533 men. Plasma was collected at entry from 2001 to 2004, and median follow-up was 5.5 years (range, 0-7.9 years). Incidence of prostate cancer as a function of plasma α-tocopherol, γ-tocopherol, and supplementation with α-tocopherol or selenomethionine was estimated by the hazard ratio (HR). Plasma γ-tocopherol was not associated with prostate cancer. Men with higher α-tocopherol concentrations seemed to have risk similar to that of men with lower concentrations [overall HR for fifth (Q5) vs. first quintile (Q1), 1.21; 95 {\%} confidence interval (CI), 0.88-1.66; P-trend = 0.24; in the trial placebo arm, Q5 HR, 0.85; 95{\%} CI, 0.44-1.62; P-trend = 0.66]. We found a strong positive plasma α-tocopherol association among men receiving the trial selenomethionine supplement [Q5 HR, 2.04; 95{\%} CI, 1.29-3.22; P-trend = 0.005]. A positive plasma α-tocopherol-prostate cancer association also seemed limited to high-grade disease (Gleason grade, 7-10; overall Q5 HR, 1.59; 95{\%} CI, 1.13-2.24; P-trend = 0.001; among men receiving selenomethionine, Q5 HR, 2.12; 95{\%} CI, 1.32-3.40; P-trend = 0.0002). Our findings indicate that higher plasma α-tocopherol concentrations may interact with selenomethionine supplements to increase high-grade prostate cancer risk, suggesting a biologic interaction between α-tocopherol and selenium itself or selenomethionine.",
author = "Demetrius Albanes and Cathee Till and Klein, {Eric A.} and Goodman, {Phyllis J.} and Mondul, {Alison M.} and Weinstein, {Stephanie J.} and Taylor, {Philip R.} and Parnes, {Howard L.} and Gaziano, {J. Michael} and Xiaoling Song and Fleshner, {Neil E.} and Brown, {Powel H.} and Meyskens, {Frank L.} and Thompson, {Ian M.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1158/1940-6207.CAPR-14-0058",
language = "English (US)",
volume = "7",
pages = "886--895",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin e Cancer Prevention Trial (SELECT)

AU - Albanes, Demetrius

AU - Till, Cathee

AU - Klein, Eric A.

AU - Goodman, Phyllis J.

AU - Mondul, Alison M.

AU - Weinstein, Stephanie J.

AU - Taylor, Philip R.

AU - Parnes, Howard L.

AU - Gaziano, J. Michael

AU - Song, Xiaoling

AU - Fleshner, Neil E.

AU - Brown, Powel H.

AU - Meyskens, Frank L.

AU - Thompson, Ian M.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - The Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed higher prostate cancer incidence in men supplemented with high-dose α-tocopherol. We, therefore, examined whether presupplementation plasma α-tocopherol or γ-tocopherol was associated with overall or high-grade prostate cancer. A stratified case-cohort sample that included 1,746 incident prostate cancer cases diagnosed through June 2009 and a subcohort of 3,211 men was derived from the SELECT trial of 35,533 men. Plasma was collected at entry from 2001 to 2004, and median follow-up was 5.5 years (range, 0-7.9 years). Incidence of prostate cancer as a function of plasma α-tocopherol, γ-tocopherol, and supplementation with α-tocopherol or selenomethionine was estimated by the hazard ratio (HR). Plasma γ-tocopherol was not associated with prostate cancer. Men with higher α-tocopherol concentrations seemed to have risk similar to that of men with lower concentrations [overall HR for fifth (Q5) vs. first quintile (Q1), 1.21; 95 % confidence interval (CI), 0.88-1.66; P-trend = 0.24; in the trial placebo arm, Q5 HR, 0.85; 95% CI, 0.44-1.62; P-trend = 0.66]. We found a strong positive plasma α-tocopherol association among men receiving the trial selenomethionine supplement [Q5 HR, 2.04; 95% CI, 1.29-3.22; P-trend = 0.005]. A positive plasma α-tocopherol-prostate cancer association also seemed limited to high-grade disease (Gleason grade, 7-10; overall Q5 HR, 1.59; 95% CI, 1.13-2.24; P-trend = 0.001; among men receiving selenomethionine, Q5 HR, 2.12; 95% CI, 1.32-3.40; P-trend = 0.0002). Our findings indicate that higher plasma α-tocopherol concentrations may interact with selenomethionine supplements to increase high-grade prostate cancer risk, suggesting a biologic interaction between α-tocopherol and selenium itself or selenomethionine.

AB - The Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed higher prostate cancer incidence in men supplemented with high-dose α-tocopherol. We, therefore, examined whether presupplementation plasma α-tocopherol or γ-tocopherol was associated with overall or high-grade prostate cancer. A stratified case-cohort sample that included 1,746 incident prostate cancer cases diagnosed through June 2009 and a subcohort of 3,211 men was derived from the SELECT trial of 35,533 men. Plasma was collected at entry from 2001 to 2004, and median follow-up was 5.5 years (range, 0-7.9 years). Incidence of prostate cancer as a function of plasma α-tocopherol, γ-tocopherol, and supplementation with α-tocopherol or selenomethionine was estimated by the hazard ratio (HR). Plasma γ-tocopherol was not associated with prostate cancer. Men with higher α-tocopherol concentrations seemed to have risk similar to that of men with lower concentrations [overall HR for fifth (Q5) vs. first quintile (Q1), 1.21; 95 % confidence interval (CI), 0.88-1.66; P-trend = 0.24; in the trial placebo arm, Q5 HR, 0.85; 95% CI, 0.44-1.62; P-trend = 0.66]. We found a strong positive plasma α-tocopherol association among men receiving the trial selenomethionine supplement [Q5 HR, 2.04; 95% CI, 1.29-3.22; P-trend = 0.005]. A positive plasma α-tocopherol-prostate cancer association also seemed limited to high-grade disease (Gleason grade, 7-10; overall Q5 HR, 1.59; 95% CI, 1.13-2.24; P-trend = 0.001; among men receiving selenomethionine, Q5 HR, 2.12; 95% CI, 1.32-3.40; P-trend = 0.0002). Our findings indicate that higher plasma α-tocopherol concentrations may interact with selenomethionine supplements to increase high-grade prostate cancer risk, suggesting a biologic interaction between α-tocopherol and selenium itself or selenomethionine.

UR - http://www.scopus.com/inward/record.url?scp=84907299493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907299493&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-14-0058

DO - 10.1158/1940-6207.CAPR-14-0058

M3 - Article

C2 - 24961880

AN - SCOPUS:84907299493

VL - 7

SP - 886

EP - 895

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 9

ER -